GoodFellas Big Board Catalyst and Chart Plays

[xtremezz]

TELK: +33% AH

Another bio with news, tomorrow should be fun - again.

Telik Announces Telintra® Clinical Publication at the 54th Annual Meeting of the American Society of Hematology

PALO ALTO, Calif., Dec. 12, 2012 /PRNewswire/ -- Telik, Inc. (TELK) announced today the publication of a clinical trial abstract in the proceedings of the 54th Annual Meeting of the American Society of Hematology in Atlanta, Georgia. The abstract, "Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, for Treatment of Patients with Myeloid Growth Factor-Resistant Idiopathic Chronic Neutropenia (ICN)," by Roger M. Lyons, MD; Sharon T. Wilks, MD; and of David J. Friedman MD, PhD, of Cancer Care Centers of South Texas, US Oncology in San Antonio, Texas; and Shelby A. Young, RN, BSN, and Gail L. Brown, MD, of Telik, Inc., in Palo Alto, California, is available online at Blood (ASH Annual Meeting Abstracts) 2012 120: Abstract 4394.

This abstract reports the preliminary results of a clinical trial with ezatiostat to study the treatment of patients with idiopathic chronic neutropenia (ICN). ICN is a rare group of blood disorders characterized by low circulating neutrophils, recurrent fevers, mucosal inflammation and serious systemic infections. The risk and severity of these complications is related to abnormally low levels of white blood cells. Most patients initially respond to treatment with granulocyte colony stimulating factors (G-CSF); however, some patients fail to respond or become resistant to G-CSF treatments. Further, G-CSF therapy is often associated with bone and muscle pain, low platelet counts and enlargement of the spleen. Patients may need to be on G-CSF for the rest of their lives, and these side effects can interfere with therapy.

http://finance.yahoo.com/news/telik-announces-telintra-clinical-publication-212000117.html